This will play a video - Renal denervation (RDN) patient with family, after Medtronic high blood pressure (HBP) treatment and hypertension (HTN) management.

IDENTIFYING POTENTIAL PATIENTS FOR RENAL DENERVATION

SELECT IDEAL PATIENTS FOR RDN

Patients who may be candidates for renal denervation (RDN) tend to fall into one of three groups. Typically, these patients are open to a balanced conversation about RDN that takes their preferences into account.

Decorative image

DIFFICULT TO CONTROL

Patients who take multiple anti-hypertensive medications and are rigorously adherent — yet still not able to control their blood pressure — are often ready for a different treatment approach. Quite simply, they know medications are not providing the results they want.

Decorative image

UNWILLING OR UNABLE TO ADHERE

The more medications a patient takes, the lower their adherence.1,2,3 Non-adherence doubles when patients move from two to three pills.1,2,3 These factors may explain why nearly half of patients become non-adherent within one year.4

Decorative image

MOTIVATED

Factors driving preference for RDN tend to be associated with how clearly the patient understands the benefits of blood pressure reduction. These factors include:

  • Personal experiences have made high blood pressure consequences real
  • Perceive high blood pressure as a significant risk
  • BP medication side effects have negatively impacted their lives

Renal Denervation: Putting Guidelines into Practice

Addressing the Population Question: Interesting Case Profiles in Renal Denervation

Dr. Tzung-Dau Wang covers important factors for identifying ideal candidates for renal denervation (RDN) and Dr. Flavio Ribichini talks about when to use RDN for patients with resistant or “difficult-to-treat” hypertension.

Professor Isabella Sudano explores how non-adherence and patient preference affect the decision to treat hypertension with renal denervation (RDN) and Professor Joachim Weil discusses how RDN can help reduce blood pressure in specific high-risk patient populations.

WHO IS A CANDIDATE FOR MEDTRONIC RDN?

SPYRAL HTN Clinical Program is aligned with the ESC/ESH Guidelines5 and ESH Statement on RDN6, focusing on patients in the context of clinical studies and taking into account patient preference.

patient selection at-a-glance chart

Medtronic is studying the use of RDN in patients between 150 and 180 mmHg office blood pressure (or between 140 and 170 mmHg ambulatory blood pressure) who are on zero to three antihypertensive medications. A broader population is also being studied in our Global Symplicity Registry.

RECONSIDER PATIENT PREFERENCE

Patients with hypertension may see renal denervation very differently than physicians. An article published in the Journal of Hypertension1 explains why many of these patients, including those not taking any medications, may prefer RDN as a way to reduce their blood pressure.

GLOBAL RDN PATIENT SELECTION GUIDELINES

As RDN gains momentum worldwide, more medical societies are developing guidelines for patient selection. 

EUROPEAN SOCIETY OF CARDIOLOGY AND EUROPEAN SOCIETY OF HYPERTENSION5,6

The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) jointly developed guidelines for the management of arterial hypertension, which cover patient selection for RDN. 

TAIWAN HYPERTENSION SOCIETY AND TAIWAN SOCIETY OF CARDIOLOGY7

The Taiwan Hypertension Society (THS) and Taiwan Society of Cardiology (TSC) issued a consensus statement on RDN, acknowledging that the procedure may benefit patient groups in addition to those with resistant hypertension. They also developed a patient selection tool.

Italian Position Paper on difficult-to-treat hypertension patients8

Published by the Italian Society of Arterial Hypertension (SIIA), the Italian position paper includes a flowchart to identify which difficult-to-treat patients should be considered for Renal Denervation. These guidelines propose a “dynamic definition” of the difficult-to-treat hypertension patient.

ASIA RENAL DENERVATION CONSORTIUM (ARDEC)9

The Asia Renal Denervation Consortium (ARDeC) consensus conference published recommendations on renal denervation (RDN) to help inform healthcare professionals in Asia. It includes five key questions to ask when considering RDN as a treatment option for hypertension.

The procedure has given me peace of mind and a new lease on life. I can’t ask for anything more.

- Gael, Hypertensive patient whose blood pressure has been under control for more than 10 years after receiving RDN.
Medtronic patient who utilizes hypertension (HTN) management and high blood pressure (HBP) treatments.

RDN isn't suitable for all patients. Individual patient outcomes may vary.

TEST YOUR HTN IQ

See how much you know about the prevalence and risks of hypertension.

TAKE THE QUIZ

COULD RDN HELP YOUR PATIENTS?

Get in touch with our team to discuss your hypertensive patients and how RDN could help them.

CONTACT US

EXTENSIVE CLINICAL EVIDENCE

The Medtronic RDN system has more published clinical evidence and patient-years of follow-up than any other RDN technology.10

SEE CLINICAL STUDIES

EXPLORE THE SYSTEM

The Symplicity Spyral™ multi-electrode renal denervation catheter is part of the Medtronic Renal Denervation system.

DISCOVER THE SYMPLICITY SPYRAL™ SYSTEM
SPYRAL Device
1

Hutchins R, Viera A, Sheridan S, et al. Quantifying the Utility of Taking Pills for Cardiovascular Prevention. Circulation: Cardiovascular Quality and Outcomes. 2015;8:155-163.

2

Gupta P, Patel P, Štrauch B, et al. Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension. 2017 Jun;69(6):v1113-1120. doi: 10.1161/ HYPERTENSIONAHA.116.08729. Epub 2017 May 1.

3

Li J, Zheng H, Du H, et al. The multiple lifestyle modification for patients with prehypertension and hypertension patients: a systematic review protocol. BMJ Open 2014;4:e004920. doi: 10.1136/bmjopen-2014-0049201

4

Jung O, Gechter J, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. Journal of Hypertension. 2013 Apr; 31(4):766-74. doi: 10.1097/HJH.0b013e32835e2286.

5

Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal, Volume 39, Issue 33, 01 September 2018, Pages 3021–3104, https://doi.org/10.1093/eurheartj/ehy339.

6

Schmieder RE, Mahfoud F, Azizi M, et al. European Society of Hypertension position paper on renal denervation 2018. J Hypertens. 2018 Oct;36(10): 2042-2048.

7

Wang TD, Lee YH, Chang SS, et. al. 2019 Consensus Statement of the Taiwan Hypertension Society and the Taiwan Society of Cardiology on Renal Denervation for the Management of Arterial Hypertension. Acta Cardiologica Sinica. 2019;35:199-230.

8

Bruno RM, Taddei S, Borghi C, et al. Italian Society of Arterial Hypertension (SIIA) Position Paper on the Role of Renal Denervation in the Management of the Difficult-to-Treat Hypertensive Patient. High Blood Press Cardiovasc Prev. 2020; 27: 109–117.

9

Kazuomi K, Byeong-Keuk K, Jiro A, et al. Renal Denervation in Asia: Consensus Statement of the Asia Renal Denervation
Consortium. Hypertension 75(3), February 2020. DOI: 10.1161/HYPERTENSIONAHA.119.13671.

10

Medtronic data on file.

All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. For distribution only in markets where the Symplicity SpyralTM multi-electrode renal denervation catheter and Symplicity G3TM renal denervation RF generator have been approved. Not for distribution in the USA, Japan or France.